The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Immunotherapy and chemo-immunotherapy for non–small cell lung cancer with novel actionable oncogenic driver alterations.
 
Laura Mazzeo
No Relationships to Disclose
 
Teresa Beninato
No Relationships to Disclose
 
Chiara Carlotta Pircher
No Relationships to Disclose
 
Marta Brambilla
No Relationships to Disclose
 
Sara Manglaviti
No Relationships to Disclose
 
Alessandro De Toma
No Relationships to Disclose
 
Giulia Galli
No Relationships to Disclose
 
Arsela Prelaj
Consulting or Advisory Role - AstraZeneca Japan; BMSi; Italfarmaco; Roche
Travel, Accommodations, Expenses - AstraZeneca Japan; BMSi; Italfarmaco; Roche
 
Roberto Ferrara
Consulting or Advisory Role - BeiGene; Merck Sharp & Dohme
 
Claudia Proto
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb; MSD; Roche
Consulting or Advisory Role - AstraZeneca Japan; MSD; Roche
Research Funding - AstraZeneca Japan; BMSi; Celgene; Daiichi Sankyo; MSD; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca Japan; MSD; Roche
 
Giuseppe Lo Russo
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb/Medarex; italfarmaco; Lilly; MSD; Novartis; Pfizer; Roche; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb/Medarex (Inst); Celgene (Inst); GlaxoSmithKline (Inst); MSD Oncology; MSD Oncology (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; BMS; MSD; Roche
 
Monica Ganzinelli
No Relationships to Disclose
 
Marina Chiara Garassino
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb; GlaxoSmithKline; MSD Oncology; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Celgene; Daiiki Sankyo; GlaxoSmithKline; Incyte; Inivata; Janssen; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche; Sanofi; Seagen; Takeda; Tiziana Life Sciences
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Celgene; Incyte; Lilly; MSD Oncology; Otsuka; Roche; Takeda
Research Funding - Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca/MedImmune (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Paolo Marchetti
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; incyte; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis; Pierre Fabre; Roche
Research Funding - AstraZeneca Japan (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); NanoString Technologies (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Incyte; Merck; Roche
 
Filippo G. De Braud
Honoraria - Amgen Astellas BioPharma; BMS; Incyte; Merck; MSD; Pfizer; Roche; Sanofi; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; EMD SERONO; Incyte; Menarini; Nerviano Medical Sciences; Nerviano Medical Sciences; Novartis Italy; Roche; Sanofi
Research Funding - Basilea Pharmaceutical; Bayer Health; Bristol-Myers Squibb/Medarex; Daiichi Sankyo Europe GmbH; Exelixis; Ignyta; incyte; Janssen Oncology; Kymab (Inst); Loxo (Inst); MedImmune; Merck KGaA; Merck Serono (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Philogen (Inst); Roche (Inst); SERVIER (Inst); Tesaro (Inst)
 
Mario Occhipinti
No Relationships to Disclose